

PATENT 1645

Case Docket No. GENENT.083A
Date: August 16, 2002

P#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Pennica et al.
Appl. No. : 09/901,812
Filed : July 10, 2001
For : METHODS FOR ENHANCING
THE EFFICACY OF CANCER
THERAPY
Examiner : Unknown
Group Art Unit : 1645

I hereby certify that this correspondence and all marked
attachments are being deposited with the United States
Postal Service as first class mail in an envelope addressed
to: United States Patent and Trademark Office, P.O. Box
2327, Arlington, VA 22202, on

August 16, 2002

(Date)

Ginger R. Dreger, Reg. No. 33,055

RECEIVED

AUG 22 2002

TRANSMITTAL LETTER

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202


TECH CENTER 1600/2900


ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement.
- (X) A PTO Form 1449 with seven (7) references which are enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Ginger R. Dreger
Registration No. 33,055
Attorney of Record



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Pennica et al.) Group Art Unit 1645
App. No. : 09/901,812)
Filed : July 10, 2001)
For : METHODS FOR)
ENHANCING THE)
EFFICACY OF CANCER)
THERAPY)
Examiner : Unknown

RECEIVED

AUG 22 2002

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing 7 references that are also enclosed. This Information Disclosure Statement is being filed before the mailing date of a final action under 37 C.F.R. § 1.113 and before the mailing date of a Notice of Allowance under § 1.311. A certification under 37 C.F.R. § 1.97(e) is set forth below. Thus, no fee is required as set forth below in 37 C.F.R. § 1.97(c).

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(1)

I hereby certify that each item of information contained in this Statement was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than


Appl. No. : 09/901,812
Filed : July 10, 2001

three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,


KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: August 16, 2001

By: 

Ginger R. Dreger
Registration No. 33,055
Attorney of Record
2040 Main Street
Fourteenth Floor
Irvine, CA 92614
(415) 954-4114

W:\DOCS\GRD\GRD-8702.DOC
081602

| | | | |
|--|--|--------------------------------|-------------------------------|
| FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. GENENT.83A | APPLICATION NO. 09/901,812 |
|  <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>USE SEVERAL SHEETS IF NECESSARY</p> | | APPLICANT Pennica et al | |
| | | FILING DATE July 10, 2001 | GROUP 1645 |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|---------------------|----|-----------------|------------|---------------|-------|----------|---------------------------------|
| | 1. | 4,997,852 | 03.05.1991 | Minton et al. | 514 | 559 | 11/13/89 |
| | | | | | | | |
| | | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|---------------------|----|-----------------|----------|---------|-------|----------|-------------|----|
| | | | | | | | YES | NO |
| | 2. | WO 95/32221 | 11/30/95 | PCT | | | | |
| | 3. | WO 01/51635 A2 | 07/19/01 | PCT | | | | |
| | | | | | | | | |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) | |
|---------------------|--|---|
| | 4. | Nagpal and Chandraratna, "Retinoids as Anti-Cancer Agents", <u>Current Pharmaceutical Design</u> , Bentham Science Publishers, 2:295-316 (1996) |
| | 5. | St-Arnaud et al., "The <i>int-1</i> proto-oncogene is transcriptionally activated during neuroectodermal differentiation of P19 mouse embryonal carcinoma cells", <u>Oncogene</u> 4(9):1077-1080 (1989) |
| | 6. | Stearns et al., "Liazarole and 13-cis-Retinoid Acid Anti-Prostatic Tumor Activity", <u>Cancer Research</u> 53(13):3072-3077 (July 1993) |
| | 7. | Tice et al., "Synergistic Induction of Tumor Antigens by Wnt-1 Signaling and Retinoid Acid Revealed by Gene Expression Profiling", <u>The Journal of Biological Chemistry</u> , US 277(16):14329-14335 (April 2002) |
| | | |
| | | |

RECEIVED
AUG 22 2002
TECH CENTER 1600/2900

| | |
|---|-----------------|
| EXAMINER | DATE CONSIDERED |
| <p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p> | |